$8.10
▲ +0.2% Today
as of Sep 4, 16:50 ET
Last 30 days
Recent Press Releases & News
Why Is ImmunityBio (IBRX) Up 9.7% Since Last Earnings Report?
SLS, IBRX Stocks Post August Gains: Eli Lilly’s Latest $2.9B Deal Has Retail Traders Bracing For An ‘M&A Rampage’
IBRX Stock Heads For Best Week In Over 2 Months After Chairman Soon Shiong’s Cancer Vaccine Trial Milestone Update
Overview
52-week range
$1.95
$12
59% of range
Avg surprise (last 3)
-12.5%
Avg reaction (last 2)
+3.3%
50% positive
Latest IV / EM
95%
EM ±4.0% · $8 · Sep 4
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.22 | — | — | — | — | financials |
| Thu May 7, 2026 | Mar/2026 | $-0.09 | $-0.08 | -12.5% | +40.0% | -7.4% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.07 | — | — | — | — | financials |
| Tue Aug 5, 2025 | Jun/2025 | $-0.10 | $-0.10 | 0.0% | — | — | earnings |
| Mon May 12, 2025 | Mar/2025 | $-0.15 | $-0.12 | -25.0% | — | +14.0% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.14 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.20 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.20 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.19 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.32 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.27 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $51M | $44M | — | $32M | $26M | $17M | — | $6M |
| Cost of revenue | $298,000 | $238,000 | — | $177,000 | $136,000 | $58,000 | — | $0 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-62M | $-70M | — | $-56M | $-71M | $-64M | — | $-80M |
| Net income | $-230M | $-633M | — | $-67M | $-93M | $-130M | — | $-86M |
| EPS (diluted) | $-0.22 | $-0.62 | — | $-0.07 | $-0.10 | $-0.15 | — | $-0.14 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $76M | $205M | $88M | $60M | $138M | $61M | $143M | $112M |
| Inventory | $2M | $547,000 | $910,000 | $7M | $7M | $8M | $8M | $2M |
| Total current assets | $439M | $453M | $315M | $329M | $208M | $109M | $185M | $163M |
| Total assets | $629M | $647M | $502M | $519M | $402M | $304M | $383M | $365M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $1.67B | $1.52B | $1.00B | $1.04B | $972M | $894M | $871M | $1.11B |
| Total equity | $-1.05B | $-869M | $-500M | $-524M | $-570M | $-590M | $-489M | $-744M |